Tikvah Therapeutics rakes in $10M for neurological drugs
Atlanta’s Tikvah Therapeutics, a specialty pharmaceutical company focused on neurological problems, raised $10 million in bridge financing, its first outside round, VentureWire reports (subscription required). The company didn’t disclose its investors beyond saying they include unnamed hedge funds and wealthy individuals.
Tikvah is currently developing a social-anxiety drug that it licensed from Therapade Technologies and a reformulated version of sodium phenylbutyrate that it hopes to use in spinal muscular atrophy.
Next Story: NeoMend pulls together $6M for wound healing
Previous Story: IPO still on hold, Light Sciences beams up $30M
About the Author, David P. Hamilton
David Hamilton has been writing for VentureBeat LifeScience since April 2007. He formerly spent 14 years as a reporter for the Wall Street Journal in its San Francisco and Tokyo bureaus. Prior to that, he spent several years as a reporter at Science Magazine and as a reporter/researcher for the New Republic, both in Washington.
VB Writers
Ben PopperEast Coast Editor
Dean TakahashiLead Writer, GamesBeat
Devindra HardawarNational Editor, MobileBeat Lead
Dylan TweneyExecutive Editor
ShoeEditor-in-Chief, GamesBeat
Heather KellySenior Editor
Jennifer Van GroveWriter
Jolie O'DellWriter
Matt MarshallFounder & Editor-in-Chief
Meghan KellyWriter
Sarah MitroffEditorial Assistant
Sean LudwigWriter
Sebastian HaleyReviews Editor, GamesBeat
Tom CheredarWriter
Ciara ByrneContributor
Julia PlevinContributor
Lindsey ComptonContributor
